颅内立体定向放疗患者脑转移速度三种预后评分的外部验证
该单中心研究纳入2014至2018年间接受颅内立体定向放疗的脑转移患者,对三种脑转移速度(BMV)评分进行外部验证。经典BMV作为分类变量和连续变量均获验证,初始BMV仅作为分类变量获验证,基于体积的BMV未能获验证。多因素分析显示初始BMV和经典BMV分别是首次SRT后和首次DBF后中危患者的总生存预测因子。
要点
- 经典BMV作为分类变量(p<0.0001)和连续变量(HR 1.02;95%CI 1.02-1.03;p<0.0001)均获外部验证。
- 初始BMV作为分类变量获验证(高危vs低危;p<0.01),作为连续变量未获验证(HR 1.02;95%CI 0.99-1.04;p=0.224)。
- 基于体积的BMV在104例亚组中未能获验证。
核心结论
- 本研究外部验证了经典BMV和初始BMV作为接受SRT的脑转移患者总生存的预后评分,而基于体积的BMV未能获得验证。
研究设计与样本
- 单中心研究,纳入2014年至2018年间接受颅内立体定向放疗的脑转移患者,共384例中333例可计算至少一种BMV评分。
- 采用对数秩检验以及线性、逻辑和Cox回归分析进行验证和总生存预测因子识别。
主要发现
- 在187例亚组中,经典BMV作为分类变量(p<0.0001)和连续变量(HR 1.02;95%CI 1.02-1.03;p<0.0001)均获验证。
- 在284例亚组中,初始BMV作为分类变量获验证(高危vs低危;p<0.01),但作为连续变量未获验证(HR 1.02;95%CI 0.99-1.04;p=0.224)。
- 基于体积的BMV在104例亚组中未能获验证。
- 多因素Cox回归分析中,首次SRT后中危患者的初始BMV为总生存预测因子(HR 1.85;95%CI 1.01-3.38;p<0.05),首次DBF后中危患者的经典BMV为总生存预测因子(HR 2.32;95%CI 1.15-4.68;p<0.05)。
- 经典BMV是高危患者总生存的主要预测因子(HR 2.99;95%CI 1.30-6.91;p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND INTRODUCTION: Brain metastasis velocity (BMV) has been proposed as a prognostic factor for overall survival (OS) in patients with brain metastases (BMs). In this study, we conducted an external validation and comparative assessment of the performance of all three BMV scores. MATERIALS AND METHODS: Patients treated with intracranial stereotactic radiotherapy (SRT) for BM at a single center between 2014 and 2018 were identified. Where possible, all three BMV scores were calculated. Log-rank tests and linear, logistic and Cox regression analysis were used for validation and predictor identification of OS. RESULTS: For 333 of 384 brain metastasis patients, at least one BMV score could be calculated. In a sub-group of 187 patients, "classic" BMV was validated as categorical (p < 0.0001) and continuous variable (HR 1.02; 95% CI 1.02-1.03; p < 0.0001). In a sub-group of 284 patients, "initial" BMV was validated as categorical variable (high-risk vs. low-risk; p < 0.01), but not as continuous variable (HR 1.02; 95% CI 0.99-1.04; p = 0.224). "Volume-based" BMV could not be validated in a sub-group of 104 patients. On multivariable Cox regression analysis, iBMV (HR 1.85; 95% CI 1.01-3.38; p < 0.05) and cBMV (HR 2.32; 95% CI 1.15 4.68; p < 0.05) were predictors for OS for intermediate-risk patients after first SRT and first DBFs, respectively. cBMV proved to be the dominant predictor for OS for high-risk patients (HR 2.99; 95% CI 1.30-6.91; p < 0.05). CONCLUSION: This study externally validated cBMV and iBMV as prognostic scores for OS in patients treated with SRT for BMs whereas validation of vBMV was not achieved.
引用
- Christ SM, Borsky K, Kraft J, et al. External validation of three prognostic scores for brain metastasis velocity in patients treated with intracranial stereotactic radiotherapy. Radiother Oncol. 2023. PMID: 37741344. doi:10.1016/j.radonc.2023.109917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。